Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome

Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy

“…This study also demonstrates that histopathology data routinely available from pre-chemotherapy core biopsies also provide substantial prognostic power (especially so for PRS score and grade). This conclusion is supported by other laboratory studies, which have included investigation of expression of the HER2 oncogene (Penault-Llorca et al, 2003) and the cellular proliferation marker Ki-67 (Aas et al, 2003). Whereas laboratory analysis of actual tissue is inherently superior to imaging alone, it should be noted that the core biopsy technique is always prone to sampling errors, whereas imaging has the advantage of covering the whole of the lesion.…”

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

“…In contrast, others have not found an independent relationship between post-neoadjuvant chemotherapy Ki67 and survival [14][15][16][17][18]. Three studies found ER status to be the sole independent predictor of DFS or RFS on multivariate analysis [14,16,19].…”

“…Three studies found ER status to be the sole independent predictor of DFS or RFS on multivariate analysis [14,16,19]. Bottini et al observed on multivariate analysis that clinical response, tumour size and PgR status were independent predictors for disease recurrence [15,20].…”

Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

“…In patients with advanced tumors, the results of the trials evaluating relationships between HER2 and response to doxorubicin are contradictory [29][30][31][32][33][34], but most studies had been retrospective and too underpowered to show clinically relevant correlations. Our study did not observe a significant relationship between HER2 gene amplification (as measured by FISH) and response to doxorubicin although, numerically, the absolute response rate for HER2 amplified tumors was higher than for HER2-normal tumors (28% vs. 16%).…”

“…The correlation between TOP2A gene status/topo2a protein expression and response to anthracyclines has been addressed by a legion of studies [23,26,30,[35][36][37][38][39][40][41][42][43][44][45][46][47] and are currently a matter of considerable debate. Most studies were essentially retrospective, and included breast cancer patients treated with anthracycline combinations rather than single agent anthracycline and, therefore, the activity of the other drugs of the combination could obscure any existing relationship.…”